PeptiDream Inc.

Tokyo Stock Exchange:4587.T

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🤖 Artificial Intelligence (AI)

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Japan

Market Cap

USD 1.45 B

Share Price

USD 11.17

Avg Daily Volume

666,901

Change (1 day)

-0.77%

Change (1 year)

-21.35%

Change (YTD)

-33.68%

PeptiDream Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -33.68%

PeptiDream Inc. Share Price Year-To-Date (YTD) return is -33.68% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

PeptiDream Inc. 52-week low Share Price is USD 19.95 on June 20, 2025, which is 78.51% above the current Share Price.
PeptiDream Inc. 52-week low Share Price is USD 11.17 on June 20, 2025, which is 0.00% below the current Share Price.
PeptiDream Inc. average Share Price for the last 52 weeks is USD 15.54.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Tokyo Stock Exchange: 4587.T

PeptiDream Inc.

CEO	Dr. Patrick Crawford Reid Ph.D.
IPO Date	June 12, 2013
Location	Japan
Headquarters	3-25-23 Tonomachi
Employees	621
Sector	🏥 Health Care
Industries Pharmaceuticals 🤖 Artificial Intelligence (AI) 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.